P2RY12 and atherosclerosis: Second, this study was limited to the four CVD medicine classes indicated for secondary prevention of ASCVD and are all shared by the respondents, we could not include P2Y12 inhibitors, aldosterone antagonists, trimetazidine, or CCBs in the DCE due to the relatively small number of surveyed patients who use such medications.